Background
==========

One of the main goals of the genomics revolution has been to characterize diversity within indigenous populations, which have traditionally been under-represented in research. The availability of genomic data is enabling researchers to identify how and why genomic variation affects individual and population differences in clinical outcomes following pharmaceutical drug administration. Additionally, evolutionary and demographic processes which have shaped population variation at clinically relevant regions of the human genome are now being determined. Studies of genes encoding drug metabolizing enzymes, such as the Cytochrome P450 (CYP450) super-family have identified variation which affects the safety and efficacy of therapeutic drugs. However little is known about intra-African variation at these loci. Africa is heavily burdened with common and infectious diseases \[[@B1]\], which are treated with multiple drugs. Studies of intra-African variation at genes encoding drug metabolizing enzymes are likely to be beneficial to clinicians, geneticists and researchers within the emerging field of evolutionary medicine \[[@B2]\]. They are also likely to have great potential for minimizing the risk of adverse clinical outcomes in patients with recent African ancestry \[[@B3]\].

CYP3A enzymes, a sub-family of the CYP450 super-family, are responsible for the phase I hepatic and intestinal metabolism of a wide spectrum of endogenous and xenobiotic compounds \[[@B4]\]. The two most clinically relevant CYP3A enzymes are CYP3A4 and CYP3A5, which together are involved in the metabolism of \~50% of all therapeutic drugs \[[@B5]\]. Because of the wide substrate range, some functional variation in *CYP3A* genes is associated with individual and population differences in pharmacogenetic profiles \[[@B6]\], adverse clinical outcomes \[[@B7]\], and elevated predisposition to diseases \[[@B8],[@B9]\].

There is considerable inter-ethnic variability in CYP3A5 expression levels \[[@B10]\]. Individuals tend to express CYP3A5 at high concentrations (21-202 pmol/mg) or have significantly reduced, often undetectable, protein levels (\<21 pmol/mg) \[[@B11]-[@B13]\]. Variability in protein expression is largely attributed to four *CYP3A5* alleles; *CYP3A5\*1*, an expresser allele, and the low/non-expresser *CYP3A5\*3, CYP3A5\*6* and *CYP3A5\*7* alleles \[[@B13],[@B14]\]. Studies have reported that the highest frequencies of high-activity alleles are found in populations with recent African ancestry \[[@B15],[@B16]\]. *CYP3A5\*3* is the main determinant of CYP3A5 expression levels in populations outside Africa \[[@B10]\]. The *CYP3A5\*6* and *CYP3A5\*7* alleles are observed almost exclusively in individuals with recent African ancestry \[[@B13]-[@B16]\], although *CYP3A5\*6* has been observed at low frequency in a sample of individuals from Los Angeles with Mexican ancestry, genotyped as part of the HapMap consortium. *CYP3A5\*7* has been observed at a frequency of 3% in ethnic Koreans \[[@B17]\]. There is some uncertainty over the functionality of the *CYP3A5\*6* mutation. Its effect on protein expression was reported in 2001 \[[@B13]\]. One of two cDNA products isolated from three *CYP3A5\*1/CYP3A5\*6* heterozygotes did not contain the sequence for exon 7. Subsequent western blot analyses of liver samples from two *CYP3A5\*1/CYP3A5\*6* heterozygotes found significantly lower protein levels than in *CYP3A5\*1* homozygotes. It has been proposed that *CYP3A5\*6* creates an aberrant splicing pathway \[[@B13]\], however this has not been confirmed experimentally. Although data presented by Kuehl *et al.* suggest that CYP3A5 expression levels in *CYP3A5\*6* carriers are lower than in *CYP3A5\*1* homozygotes, in the absence of expression analysis and more extensive *in vivo* and *in vitro* data we considered it prudent to allow for the possibility that in at least some individuals *CYP3A5\*6* is expressed. Unlike the *CYP3A5\*3* and *CYP3A5\*7* mutations, the association between *CYP3A5\*6* and clinical outcomes is not completely certain. A study examining the association between *CYP3A* genotypes and the metabolism of midazolam found a significant association between the metabolism of the drug and the presence of the *CYP3A5\*3* allele, but not the *CYP3A5\*6* allele \[[@B18]\]. However, an independent study of Japanese breast cancer patients found that tumor sizes were significantly higher in women who carried the *CYP3A5\*6* allele \[[@B19]\]. Given this uncertainty we present analyses that assume both that the *CYP3A5\*6* allele does, and does not affect protein expression and function.

A previous study reported that elevated *CYP3A5\*3* frequencies are positively correlated with increased geographic distance from the equator \[[@B20]\]. There is a latitudinal cline in the frequencies of alleles involved in heat adaptation, and consequently hypertension susceptibility \[[@B21]\]. A strong positive correlation is observed between latitude and functionally important variants of genes implicated in salt-sensitive hypertension, by regulating cardiovascular reactivity and volume avidity, such as angiotensinogen (*AGT*), G protein β3 subunit (*GNB3*), and epithelial sodium channel γ (*ENaCγ*) \[[@B21]\]. CYP3A5 is involved in the metabolism of renal cortisol to 6-β-hydroxycortisol, a key regulator of renal sodium transport, and immune responses which cause inflammation \[[@B22]\]. It has been proposed that the expresser *CYP3A5\*1* allele provides a selective advantage in equatorial populations due to the role of CYP3A5 in salt retention and the reabsorption of water \[[@B13],[@B20]\]. Conversely, elevated *CYP3A5\*1* frequencies are hypothesized to be detrimental and are associated with elevated risk of salt-sensitive hypertension in non-equatorial populations \[[@B8],[@B23],[@B24]\]. The *CYP3A5* gene region has high frequencies of derived, functional alleles \[[@B25]\], and substantial population differentiation in the frequencies of the *CYP3A5\*3* allele when compared to neutral markers, as measured by weighted *F*~ST~ tests, \[[@B26]\]. This suggests that low/non-expression of CYP3A5 may be adaptive in non-equatorial populations.

Although CYP3A5 expression in Africa is likely to be highly variable, few previous studies have characterized intra-African diversity in *CYP3A5* and other clinically relevant genes. High levels of genetic diversity are observed within the continent compared to other geographic regions, and this is consistent with a recent African origin model of human evolution \[[@B27]\]. East Africa is a particularly diverse region of the continent. Reports have shown a gradual reduction in genetic diversity with increased geographic distance from Ethiopia \[[@B28]-[@B30]\] indicating that the region is one of the most genetically diverse in the world. Studies of functional variation in clinically relevant genes have found significant inter-ethnic differences within Ethiopia and between Ethiopian and other African populations \[[@B31]-[@B33]\]. These data highlight the potential that focused genetic studies of clinically relevant variation within Ethiopian populations have for understanding intra-African genetic diversity.

Within this study we have focused on characterizing *CYP3A5* variation in multiple geographically and ethnically diverse populations sampled from in and around Africa. We focused on determining population structure at this locus, and identified considerable population structuring within Africa. These results suggest that there are likely to be multiple pharmacogenetic profiles across Africa which could affect the safety and efficacy of many therapeutic drugs which are CYP3A5 substrates. Additionally, we report correlations between CYP3A5 expression phenotypes and aridity data for 10,000 and 50,000 years ago, consistent with a previous hypothesis that the enzyme is involved in salt retention/heat adaptation. This suggests that global variability in expression phenotypes may have occurred as a result of selective pressures on the gene.

Results
=======

The prevalence of clinically relevant *CYP3A5* alleles in Africa
----------------------------------------------------------------

We genotyped 2245 individuals from 32 geographically and ethnically diverse African populations for common clinically relevant *CYP3A5* alleles. An additional 293 individuals from four non African populations from Europe and the Arabian Peninsula were also genotyped to permit comparisons of African diversity in a global context (Table [1](#T1){ref-type="table"}). Prior to our study, the distribution of clinically relevant *CYP3A5* alleles across Africa, and relative to non-African populations, was unknown. We identified *CYP3A5\*1, CYP3A5\*3* and *CYP3A5\*6* in all genotyped African population samples (allele frequency ranges: 4-81%, 4-81% and 4-33% respectively). *CYP3A5\*7* was confined almost exclusively to Niger-Congo speaking samples (range: 0-22%). The distribution of *CYP3A5* alleles is structured by major language family and geographic region, as evidenced by Analysis of Molecular Variance \[*P\<*0.0001 for both variables\]. Pearson's χ^2^ tests were carried out to examine within-region differences. Considerable heterogeneity was observed in East Africa \[χ^2^=157.69, d.f.=21, *p*\<0.0001\] and North Africa \[χ^2^=37.61, d.f.=9, *p*\<0.01\] but not in any other geographic region. The genotyped loci are in complete LD (*D´*=1, *p\<*0.0001), except between the *CYP3A5\*6* and *CYP3A5\*1/\*3* loci (*D´*=0.96, *p*\<0.0001). A low frequency recombinant haplotype was observed in 10 heterozygotes explaining why *D*´ between *CYP3A5\*1* and *CYP3A5\*6* is not equal to 1. Haplotype analysis found that the low/non-expresser *CYP3A5* alleles occur predominantly on independent haplotype backgrounds (Figure [1](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"} Table S1) suggesting that their convergent effects on CYP3A5 expression are independent. A significant correlation between pairwise genetic (*F*~ST~) and geographic distances (kilometers) was observed using a Mantel test when all populations genotyped in this study (*n*=36) were analyzed \[Mantel *r* statistic=0.228, *p*\<0.0001\].

![**The distribution of the five inferred*CYP3A5*haplotypes across the dataset.** The size of each circle is proportional to the number of individuals sampled from a given population (see Additional file [1](#S1){ref-type="supplementary-material"} Table S1). The allele combinations at all three loci are given in the key. The alleles in brackets define the inferred haplotype. N.B. the recombinant *CYP3A5* haplotype 5: *\*3/\*6,* is observed at low frequency in the dataset.](1471-2156-14-34-1){#F1}

###### 

**Genotype and allele frequencies and tests for deviation from Hardy-Weinberg Equilibrium (χ**^**2**^***p*-values given)**

  **Region**     **Country**               **Population**                   ***CYP3A5\*1/CYP3A5\*3***   ***CYP3A5\*6***   ***CYP3A5\*7***                                                                                        
  -------------- ------------------------- -------------------------------- --------------------------- ----------------- ----------------- ----- ------ ------- ----- ---- ---- ----- ------ ------ ----- ---- --- ----- ------ ------
  Europe         Armenia                   Southern Armenians               0                           10                90                100   0.95   1.00    100   0    0    100   0.00   N/A    100   0    0   100   0.00   N/A
                 Turkey                    Anatolian Turks                  2                           10                62                74    0.91   0.11    74    0    0    74    0.00   N/A    74    0    0   74    0.00   N/A
  Arabian        Yemen                     Yemeni from Hadramaut            2                           21                59                82    0.85   1.00    77    5    0    82    0.03   1.00   80    2    0   82    0.01   1.00
  Peninsula                                Yemeni from Sena and Msila       7                           17                13                37    0.58   0.74    29    7    1    37    0.12   0.42   35    2    0   37    0.03   1.00
  North Africa   Algeria                   Northern Algerians               9                           42                108               159   0.81   0.12    146   15   0    161   0.05   1.00   159   2    0   161   0.01   1.00
                 Morocco                   Berbers                          3                           28                54                85    0.80   1.00    79    7    0    86    0.04   1.00   85    1    0   86    0.01   1.00
                 Sudan                     Northern Sudanese                24                          58                51                133   0.60   0.29    104   28   0    132   0.11   0.36   135   1    0   136   0.00   1.00
                                           Sudanese from Kordofan           11                          11                8                 30    0.45   0.16    19    10   1    30    0.20   1.00   29    1    0   30    0.02   N/A
  East Africa    Ethiopia                  Afar                             10                          31                32                73    0.65   0.61    47    26   0    73    0.18   0.11   73    0    0   73    0.00   N/A
                                           Amhara                           14                          22                40                76    0.67   0.004   55    19   2    76    0.15   0.67   76    0    0   76    0.00   N/A
                                           Anuak                            38                          32                6                 76    0.29   1.00    44    25   7    76    0.26   0.23   75    1    0   76    0.01   1.00
                                           Maale                            20                          36                19                75    0.49   0.82    53    22   0    75    0.15   0.34   74    1    0   75    0.01   1.00
                                           Oromo                            12                          28                34                74    0.65   0.20    55    19   1    75    0.14   1.00   75    0    0   75    0.00   N/A
                 Republic of South Sudan   Southern Sudanese                74                          42                9                 125   0.24   0.46    58    50   15   123   0.33   0.42   117   8    0   125   0.03   1.00
                 Tanzania                  Chagga                           28                          18                4                 50    0.26   0.71    36    14   0    50    0.14   0.57   41    9    0   50    0.09   1.00
                 Uganda                    Bantu speakers from Ssese        36                          3                 0                 39    0.04   1.00    22    17   0    39    0.22   0.16   23    16   0   39    0.21   0.31
  West Africa    Ghana                     Asante                           27                          8                 0                 35    0.11   1.00    20    13   1    34    0.22   1.00   29    5    0   34    0.07   1.00
                                           Bulsa                            58                          29                3                 90    0.19   1.00    61    28   0    89    0.16   0.11   69    19   2   90    0.13   0.62
                                           Kasena                           28                          17                2                 47    0.22   1.00    31    16   0    47    0.17   0.32   35    12   0   47    0.13   1.00
                 Senegal                   Manjak                           57                          29                4                 90    0.21   1.00    59    24   9    92    0.23   0.02   81    13   0   94    0.07   1.00
                                           Wolof                            55                          31                8                 94    0.25   0.27    58    31   1    90    0.18   0.29   78    15   1   94    0.09   0.55
  West Central   Cameroon                  Kotoko                           18                          21                0                 39    0.27   0.04    23    16   1    40    0.23   0.65   36    4    0   40    0.05   1.00
  Africa                                   Shewa Arabs                      26                          31                12                69    0.40   0.62    42    24   3    69    0.22   1.00   60    9    0   69    0.07   1.00
                                           Mayo Darle                       66                          38                13                117   0.27   0.06    71    33   13   117   0.25   0.01   102   15   0   117   0.06   1.00
                                           Somie, Cameroonian Grassfields   36                          28                1                 65    0.23   0.16    44    19   2    65    0.18   1.00   52    13   0   65    0.10   1.00
                 Congo                     Congolese from Brazzaville       35                          18                2                 55    0.20   1.00    43    11   1    55    0.12   0.55   45    10   0   55    0.09   1.00
                 Nigeria                   Igbo                             64                          23                0                 87    0.13   0.35    60    24   4    88    0.18   0.47   73    12   2   87    0.09   0.14
  South East     Malawi                    Chewa                            66                          25                1                 92    0.15   1.00    66    23   3    92    0.16   0.69   60    31   0   91    0.17   0.06
  Africa                                   Lomwe                            13                          4                 1                 18    0.17   N/A     10    8    0    18    0.22   N/A    14    4    0   18    0.11   N/A
                                           Ngoni                            15                          2                 1                 18    0.11   N/A     9     6    3    18    0.33   N/A    16    2    0   18    0.06   N/A
                                           Tumbuka                          44                          18                0                 62    0.15   0.34    40    17   5    62    0.22   0.14   45    17   0   62    0.14   0.59
                                           Yao                              37                          18                1                 56    0.18   0.67    43    12   1    56    0.13   1.00   46    10   0   56    0.09   1.00
                 Mozambique                Sena                             58                          21                3                 82    0.16   0.44    51    28   5    84    0.23   0.75   59    25   1   85    0.16   0.68
                 South Africa              Bantu speakers                   22                          17                2                 41    0.26   1.00    29    9    3    41    0.18   0.10   34    4    2   40    0.10   0.03
                 Zimbabwe                  Lemba                            17                          6                 0                 23    0.13   1.00    13    10   1    24    0.25   1.00   17    7    0   24    0.15   1.00
                                           Zimbabweans from Mposi           36                          7                 4                 47    0.16   0.008   36    10   3    49    0.16   0.09   34    16   2   52    0.19   1.00

HWE could not be calculated for the Lomwe and Ngoni as both populations had fewer than 50 chromosomes meaning that the test had insufficient power. No population deviated from Hardy-Weinberg equilibrium, following Bonferonni correction (for *CYP3A5\**3: adjusted *p* value = 0.00139; correction for 36 tests, for *CYP3A5\*6*: adjusted *p* value=0.0015; correction for 34 tests, for *CYP3A5\*7:* adjusted *p* value=0.0017; correction for 30 tests). Deviations from HWE cannot be calculated for monomorphic loci: labeled "N/A" on the Table. "Total" refers to the number of individuals, from a given population, successfully genotyped at each locus. Population refers to the grouping of individuals either by self-declared ethnicity or geography/place collected.

The geographic and ethnic distributions of low-, intermediate- and high-expression phenotypes, based on haplotype frequencies were inferred. Expresser phenotypes were inferred assuming that *CYP3A5\*6* does and does not cause a low/non-expression phenotype (Additional file [2](#S2){ref-type="supplementary-material"} Figure S1 and Additional file [3](#S3){ref-type="supplementary-material"} Figure S2 respectively). The distributions in both Figures show that the highest frequencies of high-activity phenotypes are in equatorial regions of Africa, and Ethiopia has the highest within country inter-ethnic diversity, which is driven by differences between the Anuak and other Ethiopian groups.

*Correlations between ecological variables and inferred* CYP3A5 *expression phenotypes*
---------------------------------------------------------------------------------------

A previous study reported a strong positive correlation between *CYP3A5\*3* allele frequencies and latitude \[[@B20]\]. Latitude is a correlate of multiple ecological variables that are associated with functional markers of genes involved in heat adaptation \[[@B21]\]. We tested for correlations between frequencies of low/non-expresser *CYP3A5* alleles, and inferred expresser phenotypes, with latitude and the ecological variables; temperature and precipitation (Table [2](#T2){ref-type="table"}). Additionally, we tested for correlations with aridity indices calculated from temperature and precipitation data using the de Martonne aridity index \[[@B34]\]. This enabled us to consider the combined effect of temperature and precipitation on CYP3A5 phenotypes. Correlations were estimated using ecological data for the present day, and inferred for 10, 000 years ago (Holocene) and 50,000 years ago (Late Pleistocene) (<http://badc.nerc.ac.uk/home/index.html>). Correlations were performed assuming that *CYP3A5\*6* is a low/non-expresser allele, and that it is a neutral allele.

###### 

**Correlation analyses, between ecological variables and*CYP3A5*allelic and inferred expression data**

  **Time period**        **Ecological variable**   ***N=87***        ***N*=36**                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ---------------------- ------------------------- ----------------- ----------------- ----------------- ------------------------------------------------------------------------------ ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------- --------- --------------- --------- --------------- --------- ---------------
                                                   ***CYP3A5\*3***   ***CYP3A5\*6***   ***CYP3A5\*7***   **High expresser allele (assuming*CYP3A5\*6*is a low/non-expresser allele)**   **Low expresser allele (assuming*CYP3A5\*6*is a low/non-expresser allele)**   **High expresser allele (assuming*CYP3A5\*6*is not a low/non-expresser allele)**   **Low expresser allele (assuming*CYP3A5\*6*is not a low/non-expresser allele)**                                                                                 
                                                   **Rho**           ***P*-value**     **Rho**           ***P*-value**                                                                  **Rho**                                                                       ***P*-value**                                                                      **Rho**                                                                           ***P*-value**   **Rho**   ***P*-value**   **Rho**   ***P*-value**   **Rho**   ***P*-value**
                         **Latitude**              0.706             **\<0.0001**      −0.331            **0.048**                                                                      −0.177                                                                        0.303                                                                              −0.472                                                                            **0.004**       0.472     **0.004**       −0.416    **0.012**       0.416     **0.012**
                         **North latitude**        0.666             **\<0.0001**      −0.621            **0.001**                                                                      −0.410                                                                        **0.047**                                                                          −0.659                                                                            **\<0.0001**    0.659     **\<0.0001**    −0.620    **0.001**       0.620     **0.001**
                         **South latitude**        0.066             0.759             0.318             0.130                                                                          0.122                                                                         0.571                                                                              −0.701                                                                            **\<0.0001**    0.701     **\<0.0001**    −0.370    0.075           0.370     0.075
                         **Temperature**           −0.664            **\<0.0001**      0.268             0.114                                                                          0.494                                                                         **0.002**                                                                          0.655                                                                             **\<0.0001**    −0.655    **\<0.0001**    0.627     **\<0.0001**    −0.627    **\<0.0001**
  **Present Day**        **Precipitation**         −0.129            0.232             −0.290            0.867                                                                          −0.150                                                                        0.384                                                                              −0.028                                                                            0.869           0.028     0.869           0.113     0.511           −0.113    0.511
                         **Aridity**               0.286             **0.007**         −0.201            0.24                                                                           −0.267                                                                        0.116                                                                              −0.185                                                                            0.279           0.185     0.279           −0.029    0.868           0.029     0.868
                         **Temperature**           −0.597            **\<0.0001**      0.216             0.207                                                                          0.342                                                                         **0.041**                                                                          0.560                                                                             **0.0004**      −0.560    **0.0003**      0.635     **\<0.0001**    −0.635    **\<0.0001**
  **Holocene**           **Precipitation**         0.072             0.510             −0.235            0.167                                                                          −0.522                                                                        **0.001**                                                                          −0.381                                                                            **0.022**       0.381     **0.022**       −0.190    0.266           0.190     0.266
                         **Aridity**               0.471             **\<0.0001**      −0.344            **0.04**                                                                       −0.575                                                                        **0.0002**                                                                         −0.465                                                                            **0.004**       0.465     **0.004**       −0.293    0.083           0.293     0.0832
                         **Temperature**           −0.644            **\<0.0001**      0.297             0.079                                                                          0.608                                                                         **\<0.0001**                                                                       0.649                                                                             **\<0.0001**    −0.649    **\<0.0001**    0.641     **\<0.0001**    −0.641    **\<0.0001**
  **Late Pleistocene**   **Precipitation**         0.160             0.139             −0.238            0.163                                                                          −0.353                                                                        **0.035**                                                                          −0.204                                                                            0.233           0.204     0.233           −0.023    0.892           0.023     0.892
                         **Aridity**               0.532             **\<0.0001**      −0.436            **0.008**                                                                      −0.480                                                                        **0.003**                                                                          −0.379                                                                            **0.026**       0.379     **0.023**       −0.211    0.216           0.211     0.216

For analyses with inferred CYP3A5 expression phenotypes high-, intermediate- and low- expression diplotypes were counted as genotypes and the frequencies of expresser and low/non-expresser alleles calculated. For analyses with phenotypes, *CYP3A5\*6* was considered to cause low/non-expression and to have no effect on CYP3A5 expression. Significant *p*-values, at the 5% level, are shown in bold. Rho indicates Spearmann's Rho. "*N"* refers to the number of populations analyzed for each *CYP3A5* allele. For *CYP3A5\*3* frequencies, African data were combined with those previously reported \[[@B20]\]. For *CYP3A5\**6 and *CYP3A5\*7* correlations, only African data genotyped for this study were tested. North latitude and south latitude correlations were only performed with populations genotyped for this study.

Latitude correlated significantly with CYP3A5 expression in Africa \[Spearmann's Rho= −0.472, *p*=0.004\], the correlation remained significant when considering north \[Spearmann's Rho= −0.659, *p*\<0.0001\] and south latitude \[Spearmann's Rho= −0.701, *p*\<0.0001\] populations separately. Across a global cohort (87 populations) which, included published genotyping data \[[@B20]\] and where *CYP3A5\*3* alone is considered to predict CYP3A5 expression levels, a significant correlation between latitude and frequencies of this allele was seen only for north latitude populations \[Spearmann's Rho= 0.666, *p*\<0.0001\], but not south \[Spearmann's Rho= 0.066, *p*=0.759\]. No significant correlation was observed between aridity values for the present day and expresser phenotypes when *CYP3A5\*6* was considered a low/non expresser allele \[Spearmann's Rho= −0.185, *p*=0.279\] or a neutral allele \[Spearmann's Rho= −0.0288, *p*=0.868\]. Expresser phenotypes correlated significantly with aridity values from the Holocene \[Spearmann's Rho= −0.465, *p*=0.004\] and Late Pleistocene \[Spearmann's Rho= −0.379, *p*=0.02\] when *CYP3A5\*6* was considered as a low/non-expresser mutation. We subsequently examined independent correlations between expresser allele frequencies and temperature and precipitation. We found significant correlations between expresser allele frequencies and temperature for every time period, both when *CYP3A5\*6* was considered to be a low/non-expresser mutation and a neutral allele (*p*\<0.0001 for every correlation, see Table [2](#T2){ref-type="table"}). No significant correlation was observed between precipitation values and expresser allele frequencies.

We subsequently examined the correlations between present day ecological data and expresser allele frequencies, while controlling for geographic distances between populations, using partial Mantel tests. For each correlation *CYP3A5\*6* was assumed to be a low/non-expresser mutation. We found that the correlation between CYP3A5 expresser alleles and temperature remained significant when controlling for geographic proximity between populations \[Mantel *r* statistic=0.398, *p*=0.02\]. However the correlation with latitude was no longer significant \[Mantel *r* statistic=0.202, *p*=0.05\].

*CYP3A5* variation observed in Ethiopia
---------------------------------------

Previous studies of genetic variation in drug metabolizing enzymes have identified considerable inter-ethnic diversity within Ethiopia and between Ethiopian and other African populations \[[@B31]-[@B33]\]. The results from our geographic survey of clinically relevant *CYP3A5* variants also indicated that there is considerable heterogeneity within Ethiopia, and between Ethiopia and other African populations. We performed a re-sequencing survey of the *CYP3A5* gene in five Ethiopian populations to characterize *CYP3A5* diversity in greater detail.

We observed significant inter-ethnic diversity in *CYP3A5* allele frequencies in Ethiopia. To identify additional variation and elucidate intra-Ethiopian population structure we re-sequenced an 8063bp region of *CYP3A5,* which included the *CYP3A5* promoter, exons and exon-flanking introns, in five Ethiopian populations. 51 polymorphic sites were identified (Table [3](#T3){ref-type="table"}). Nine (17.6%) were exonic and, 3 out of 5 (6%) identified non-synonymous polymorphisms were predicted to adversely alter protein function. No significant difference in the proportion of synonymous or non-synonymous variation was identified by a codon-based Z-test \[[@B35]\] (*Z=*0.961 and *p=*0.169). The proportion of amino acid changes that we observed at the *CYP3A5* gene (5 changes/502 codons= \~1%) is higher than previously reported for 103 protein-coding genes (147 changes/26,999 codons=0.56%) \[[@B36]\], although the differences are not significant \[paired *t* test, *t*=1.01, d.f.=1, *p*=0.50\]. We did not identify any variants in experimentally established transcription factor binding sites \[[@B37],[@B38]\]. Eight of the nine identified promoter variants occurred in nucleotide positions that are highly conserved in primates (i.e. where the allele is the same in all primate species), and bioinformatic analyses predicted that four out of nine may affect transcription factor binding. Of all identified polymorphisms -- predicted and previously reported to affect CYP3A5 expression and activity (*n=*10) -- 4 (2 promoter, *CYP3A5\*3* and *CYP3A5\**6) occurred at frequencies over 1%. The highest frequency variants identified were *CYP3A5\*3, CYP3A5\*6* and the non-functional variant rs15524, which is found in high LD with *CYP3A5\*3*\[[@B39]\].

###### 

**All polymorphic sites identified in an 8063bp*CYP3A5*region re-sequenced in five Ethiopian populations**

                                                                                                                                                                                                       **Afar**   **Amhara**   **Anuak**   **Maale**   **Oromo**   **Total**                                                 
  ----------------------- ------------------------------ ---------------------------------------------------------------------------- ------------------------------ --------------------------------- ---------- ------------ ----------- ----------- ----------- ----------- --------- ------- --------- ------- --------- -------
  **Region of*CYP3A5***   **Position on chromosome 7**   **Position relative to the translation initiation codon (A of ATG is +1)**   **dbSNP database refSNP ID**   **Effect**                        ***f***    **n**        ***f***     **n**       ***f***     **n**       ***f***   **n**   ***f***   **n**   ***f***   **n**
  **Promoter**            99278314                       −795 T\>A                                                                    rs3823812                                                        0.00       3            0.00        3           0.01        4           0.01      10      0.01      5       0.0331    25
  **Promoter**            99278267                       −748 C\>G                                                                                                                                     0.01       5            0.00        2           0.00        1           0.00      1       0.01      6       0.0198    15
  **Promoter**            99278224                       −705 3 base pair deletion                                                                                                                     0.00       1            0.00        1           0.01        5           0.00      1       0.00      3       0.0146    11
  **Promoter**            99278223                       −704 A\>G                                                                                                                                     0.00       0            0.00        0           0.00        0           0.00      1       0.00      0       0.0013    1
  **Promoter**            99278152                       −633 C\>A                                                                                                                                     0.00       0            0.00        0           0.00        0           0.00      0       0.00      1       0.0013    1
  **Promoter**            99278146                       −627 G\>A                                                                                                                                     0.00       0            0.00        0           0.00        1           0.00      0       0.00      0       0.0013    1
  **Promoter**            99278144                       −625 A\>G                                                                                                                                     0.00       0            0.00        0           0.00        0           0.00      1       0.00      0       0.0013    1
  **Promoter**            99278070                       −551 C\>A                                                                    rs28365079                                                       0.01       4            0.01        5           0.02        15          0.01      8       0.01      4       0.0476    36
  **Promoter**            99277988                       −469 G\>A                                                                                                                                     0.00       0            0.00        0           0.00        0           0.00      1       0.00      0       0.0013    1
  **UTR of exon 1**       99277593                       −74 C\>T                                                                     rs28371764                                                       0.00       2            0.01        6           0.00        0           0.00      2       0.00      2       0.0158    12
  **UTR of exon 1**       99277544                       −25 A\>C                                                                                                                                      0.00       0            0.00        0           0.00        0           0.00      0       0.00      1       0.0013    1
  **Intron 1**            99277392                       127 G\>A                                                                                                                                      0.00       0            0.00        0           0.00        1           0.00      2       0.00      0       0.0040    3
  **Intron 1**            99277337                       182 C\>A                                                                                                                                      0.00       0            0.00        0           0.00        3           0.00      0       0.00      0       0.0040    3
  **Intron 2**            99272310                       5209 C\>T                                                                    rs28365067                                                       0.01       11           0.02        12          0.01        5           0.01      8       0.01      8       0.0580    44
  **Intron 2**            99272290                       5229 G\>A                                                                    rs41301652                                                       0.00       0            0.00        0           0.00        2           0.00      0       0.00      0       0.0026    2
  **Intron 2**            99272275                       5244 C\>T                                                                                                                                     0.00       0            0.00        0           0.00        0           0.00      0       0.00      2       0.0026    2
  **Intron 3**            99272103                       5416 C\>T                                                                                                                                     0.00       0            0.00        0           0.00        0           0.00      0       0.00      2       0.0026    2
  **Intron 3**            99272009                       5510 T\>A                                                                    rs28969392                                                       0.01       6            0.01        4           0.01        10          0.01      9       0.00      3       0.0422    32
  **Intron 3**            99271928                       5591 C\>T                                                                    rs41301655                                                       0.00       0            0.01        4           0.00        1           0.00      0       0.00      2       0.0092    7
  **Intron 3**            99271853                       5666 A\>G                                                                    rs41301658                                                       0.00       1            0.00        1           0.00        3           0.01      7       0.00      2       0.0185    14
  **Intron 3**            99271808                       5711 A\>G                                                                    rs41258334                                                       0.01       11           0.01        11          0.01        5           0.01      9       0.01      8       0.0580    44
  **Intron 3**            99271778                       5741 A\>G                                                                                                                                     0.01       6            0.00        3           0.01        4           0.01      8       0.00      3       0.0317    24
  **Intron 3**            99270539                       6980 A\>G                                                                    rs776746                       Defines the variant *CYP3A5\*3*   0.13       95           0.14        102         0.06        44          0.10      75      0.13      97      0.5581    413
  **Intron 3**            99270504                       7015 3 base pair deletion                                                                                                                     0.00       0            0.00        0           0.00        0           0.00      1       0.00      0       0.0014    1
  **Intron 3**            99270318                       7201 C\>T                                                                    rs8175345                                                        0.00       0            0.00        1           0.01        9           0.00      0       0.00      1       0.0149    11
  **Exon 4**              99270249                       7270 G\>A                                                                                                   G77S                              0.00       0            0.00        0           0.00        0           0.00      1       0.00      0       0.0014    1
  **Intron 4**            99270164                       7355 C\>T                                                                    rs28365074                                                       0.00       0            0.00        0           0.00        1           0.00      0       0.00      2       0.0041    3
  **Intron 5**            99264352                       13167 T\>C                                                                   rs68178885                                                       0.00       3            0.00        2           0.00        1           0.00      3       0.00      1       0.0132    10
  **Intron 6**            99264149                       13370 G\>A                                                                   rs41301670                                                       0.00       0            0.00        0           0.00        0           0.00      0       0.00      2       0.0027    2
  **Exon 7**              99262835                       14684 G\>A                                                                   rs10264272                     Defines the variant *CYP3A5\*6*   0.04       28           0.03        23          0.05        39          0.03      23      0.03      21      0.1763    134
  **Exon 7**              99262793                       14726 A\>G                                                                   rs2838372                      Synonymous                        0.00       1            0.00        0           0.00        0           0.00      0       0.00      0       0.0013    1
  **Intron 7**            99262642                       14877 A\>G                                                                                                                                    0.00       1            0.01        5           0.02        12          0.01      9       0.00      2       0.0382    29
  **Intron 7**            99261737                       15782 T\>C                                                                   rs28969393                                                       0.01       5            0.01        4           0.01        9           0.01      9       0.00      3       0.0396    30
  **Exon 8**              99261651                       15868 A\>G                                                                                                  K266R                             0.00       0            0.00        0           0.00        1           0.00      0       0.00      0       0.0013    1
  **Intron 8**            99261583                       15936 C\>A                                                                                                                                    0.00       0            0.00        0           0.00        0           0.00      2       0.00      0       0.0026    2
  **Intron 8**            99260546                       16973 G\>A                                                                                                                                    0.00       0            0.00        1           0.00        0           0.00      0       0.00      0       0.0013    1
  **Exon 9**              99260502                       17017 C\>T                                                                                                  R268Stop                          0.00       0            0.00        0           0.00        1           0.00      0       0.00      0       0.0013    1
  **Intron 9**            99260407                       17112 C\>T                                                                   rs28383478                                                       0.00       0            0.00        2           0.00        0           0.00      0       0.00      0       0.0026    2
  **Intron 9**            99260362                       17157 G\>T                                                                   rs4646453                                                        0.00       3            0.00        3           0.01        4           0.01      10      0.01      5       0.0331    25
  **Intron 9**            99260282                       17237 T\>G                                                                                                                                    0.00       0            0.00        0           0.00        1           0.00      0       0.00      0       0.0013    1
  **Intron 9**            99260170                       17349 T\>G                                                                                                                                    0.00       3            0.00        2           0.01        7           0.01      7       0.00      3       0.0291    22
  **Intron 9**            99258524                       18995 C\>T                                                                   rs10247580                                                       0.00       0            0.00        2           0.02        12          0.01      7       0.00      1       0.0291    22
  **Intron 9**            99258320                       19199 G\>A                                                                                                                                    0.00       0            0.00        0           0.00        1           0.00      0       0.00      0       0.0013    1
  **Intron 9**            99258316                       19203 T\>C                                                                                                                                    0.00       0            0.00        0           0.00        0           0.00      2       0.00      0       0.0026    2
  **Exon 10**             99258124                       19395 A\>C                                                                                                  K342T                             0.00       0            0.00        0           0.00        0           0.00      0       0.00      1       0.0013    1
  **Exon 11**             99250397                       27125-27126 T insertion                                                      rs41303343                     Defines the variant *CYP3A5\*7*   0.00       0            0.00        0           0.00        1           0.00      1       0.00      0       0.0026    2
  **Exon 11**             99250381                       27138 A\>G                                                                                                  V350M                             0.00       0            0.00        0           0.00        1           0.00      0       0.00      0       0.0013    1
  **Intron 12**           99247647                       29872 G\>T                                                                                                                                    0.00       0            0.00        0           0.00        0           0.00      2       0.00      0       0.0026    2
  **Intron 12**           99247503                       30016 1 base pair deletion                                                   rs28365093                                                       0.00       3            0.01        4           0.02        15          0.01      8       0.01      4       0.0450    34
  **Intron 12**           99246026                       31493 T\>C                                                                   rs28365069                                                       0.01       4            0.01        11          0.01        11          0.02      18      0.01      9       0.0699    53
  **3\' UTR**             99245914                       31605 C\>T                                                                   rs15524                                                          0.14       105          0.14        109         0.09        69          0.11      84      0.14      107     0.6253    474

*n* refers to the total number of chromosomes on which a particular variant was observed. *f* is the relative frequency of each variant. Total refers to the number of times a variant was observed in the Ethiopian cohort (758 chromosomes) and *f* is its relative frequency. Position on chromosome 7 is based on NCBI Build 132, February 2009.

Ethiopian *CYP3A5* variation in the context of other geographic populations
---------------------------------------------------------------------------

We analyzed the Ethiopian re-sequencing data along with those previously reported for three ethnically diverse populations from the Corriell Repositories to analyze the data in a global context \[[@B20]\] (Table [4](#T4){ref-type="table"}). The results of the Hudson-Kreitman-Aguadé (HKA) test \[[@B40]\], comparing intra- and inter-species *CYP3A5* diversity, was not significant (*p=*0.6346). Tajima's *D*, Li's *D\** and *F\**, Fu and Li's *F* and *D* (using chimpanzee sequence to establish ancestral states), and Fu's *F*~*S*~ all indicated a skew towards rare variants in every population, which is consistent with general human population growth or positive selection. Fu and Li's *D\** and *F\** reported a significant departure from neutrality for both Europeans and the Anuak, although significance was only reached for Europeans following Bonferonni correction (8 tests). Fu and Li's *F*~*S*~ reported a significant departure from neutrality for 7 of the 8 populations after Bonferonni correction. Strobeck's *S* results were consistent with Fu's *F*~*S*~*,* as expected. The results of the *H* test, used to assess whether there is an excess of high frequency derived variants \[[@B41]\], were not significant in any population (*p\>*0.05), however nucleotide diversity at *CYP3A5* is low and this may be affecting the tests.

###### 

**A summary of the tests for departures from neutrality for an 8063bp region of*CYP3A5***

                                 **Global populations**   **Ethiopian populations**                                                                              
  ------------------------------ ------------------------ --------------------------- -------------- -------------- -------------- -------------- -------------- --------------
  **Sample size**                23                       24                          23             75             76             76             76             76
  **Nucleotide diversity (π)**   5.4 x 10^-4^             9 x 10^-5^                  1.1 x 10^-4^   2.1 x 10^-4^   2.5 x 10^-4^   3.6 x 10^-4^   3.5 x 10^-4^   2.2 x 10^-4^
  **McDonald-Kreitman test**     0.475                    0.50                        0.777          0.462          0.475          0.576          1.00           0.777
  **Tajima's*D***                −1.04                    −1.92                       −1.21          −1.46          −1.13          −1.26          −0.96          −1.79
  **Fu and Li's*D\****           −0.97                    **−2.86**                   −1.82          −1.19          0.12           −2.72          −0.11          −1.05
  **Fu and Li's*F\****           −1.17                    **−3.00**                   −1.91          −1.54          −0.43          −2.57          −0.53          −1.58
  **Fu and Li's*D***             −0.64                    −1.37                       −1.45          −1.56          −0.08          −1.93          0.73           −0.96
  **Fu and Li's*F***             −0.92                    −1.81                       −1.55          −1.79          −0.52          −1.96          0.13           −1.48
  **Fu's*F***~***S***~           **−31.06**               **−5.71**                   −1.54          **−9.48**      **−11.74**     **−18.44**     **−11.08**     **−22.84**
  **Strobeck's*S***              **1.00**                 **0.999**                   0.929          **1.00**       **1.00**       **1.00**       **1.00**       **1.00**
  **Fay and Wu's*H*statistic**   −0.13140                 −3.25532                    −1.89372       0.10774        −0.23998       −0.47177       −0.87086       −1.75514

Statistically significant departures from neutrality, following Bonferonni correction (correction for 8 tests; adjusted *p*≤0.00625) are shown in bold.

###### 

**Pairwise*F***~**ST**~**values for five Ethiopian populations and three other global populations**

                          **Afar**   **Amhara**   **Anuak**       **Maale**     **Oromo**       **African-Americans**   **Europeans**   **Han Chinese**
  ----------------------- ---------- ------------ --------------- ------------- --------------- ----------------------- --------------- -----------------
  **Afar**                **\***     0.74597      **\<0.00001**   **0.00436**   0.76537         **\<0.00001**           **\<0.00001**   **\<0.00001**
  **Amhara**              −0.00248   **\***       **\<0.00001**   **0.00347**   0.93525         **\<0.00001**           **\<0.00001**   **\<0.00001**
  **Anuak**               0.04566    0.05138      **\***          **0.00257**   **\<0.00001**   **\<0.00001**           **\<0.00001**   **\<0.00001**
  **Maale**               0.01951    0.01736      0.01061         **\***        **0.00267**     **\<0.00001**           **\<0.00001**   **\<0.00001**
  **Oromo**               −0.00255   −0.0036      0.04981         0.01547       **\***          **\<0.00001**           **\<0.00001**   **\<0.00001**
  **African-Americans**   0.08997    0.09366      0.01558         0.03432       0.08803         **\***                  **\<0.00001**   **\<0.00001**
  **Europeans**           0.04873    0.03807      0.15448         0.08716       0.03371         0.19028                 **\***          **0.00257**
  **Han Chinese**         0.10812    0.0893       0.23763         0.16215       0.09715         0.29154                 0.0677          **\***

Pairwise *F*~ST~ values are shown in the bottom left side of the Table, the corresponding *p-*values are shown in the top right of the Table. *P*-values which are significant after Bonferroni correction (adjusted *p*-value = 0.00625; correction for 8 tests) are shown in bold.

###### 

**Age estimates of clinically relevant*CYP3A5*variants**

  ***CYP3A5*variant**   **Location on chromosome 7**   **Location in gene**   **Allele dated**   **Number of chromosomes**   **Average squared distance (ASD)**    **Time to most recent common ancestor**  **95% confidence intervals of allele age estimate based on a star phylogeny**                                                   
  --------------------- ------------------------------ ---------------------- ------------------ --------------------------- ------------------------------------ ----------------------------------------- ------------------------------------------------------------------------------- ----------------- ----------- ----------------- -----------
                                                                                                                                                                         **Estimate of allele age**         **Lower**                                                                           **Upper**                                   
                                                                                                                                                                               **Generations**              **Years**                                                                        **Generations**  **Years**    **Generations**  **Years**
  ***CYP3A5\*3***       99270539                       Intron 3               G                  134                         1.0746                                                 2388                    76,416                                                                                1797        57,504            3211        102,752
  ***CYP3A5\*6***       99262835                       Exon 7                 A                  18                          3.0714                                                 6825                    218,400                                                                               3086        98.752            11975       383,200
  **rs15524**           99245914                       3´ UTR                 T                  324                         1.8426                                                 4095                    131,040                                                                               3157        101,024           5413        173,216

Allele ages were estimated using a mutation rate of 0.00045 and a generation time of 32 years. The confidence intervals for the estimated age of the *CYP3A5\*6* are large; most likely a reflection of the small sample size. UTR is the Untranslated Region.

72 haplotypes were inferred from allelic data for all 8 Ethiopian population samples, 33 (45.8%) containing *CYP3A5\*1,* 29 (40.3%) containing *CYP3A5\*3,* 7 (9.7%) containing *CYP3A5\*6*, 1 (1.4%) containing *CYP3A5\*7*, and 2 (2.8%) containing both *CYP3A5\*3* and *CYP3A5\*6* (Additional file [4](#S4){ref-type="supplementary-material"} Figures S3a and b). LD across the gene is high. A phylogeny, based on network analysis of the haplotype data, is presented in Figure [2](#F2){ref-type="fig"}. 98% of European and 83% of Han Chinese haplotypes contain the *CYP3A5\*3* allele, as do \~64% of Afar haplotypes and \~67% in both the Amhara and Oromo. Gene diversity is highest in African Americans (0.963 ± 0.02) and lowest in Europeans (0.589 ± 0.08). The *CYP3A5\*1* haplogroup is significantly more diverse than the other haplogroups (0.921 ± 0.01) (*p\<*0.0001 for every comparison). Population differentiation was measured by pairwise *F*~ST~ (Table [5](#T5){ref-type="table"}). The Afar, Amhara and Oromo are intermediate between individuals with recent African ancestry and Han Chinese and European groups. We placed population structure seen at the *CYP3A5* gene in a wider genomic context by analyzing intra-Ethiopian differentiation at markers on the non-recombining regions of the Y chromosome (NRY) and the mitochondrial genome (hypervariable region 1 \[HVS1\] and coding region SNPs) \[[@B42]\]. We compared Ethiopian NRY and HVS1 genotypes with data for 92 Fars from Iran, 95 Nigerian Igbo, 126 Greek-Cypriots and 60 Halfawi from the Republic of Sudan. The Anuak are outliers compared to the other Ethiopian populations (data not shown), consistent with genome wide-markers \[[@B43]\] and what we report for *CYP3A5*. Intra-Ethiopian population structure at the *CYP3A5* gene is also consistent with that seen at other drug metabolizing genes *CYP1A2*\[[@B31]\], and *UGT1A1*\[[@B32]\].

![**A network of all*CYP3A5*haplotypes inferred for Ethiopians and Coriell populations.** Networks assume single mutational steps. Haplotypes are colored according to the haplogroup to which they belong; haplotypes which are defined by the *CYP3A5\*3* allele are shown in red; those defined by *CYP3A5\*1* in yellow; *CYP3A5\*7* in green; *CYP3A5\*6* in blue and *CYP3A5\*3/\*6* recombinant haplotypes are shown in purple. The size of each haplotype is proportional to its frequency in the global database. Additional file [4](#S4){ref-type="supplementary-material"} Figure S3a contains information on the exact composition of each coded haplotype.](1471-2156-14-34-2){#F2}

Estimating the age of clinically relevant *CYP3A5* alleles
----------------------------------------------------------

The age of an allele is the time since it arose by mutation \[[@B44],[@B45]\]. Estimating the ages of *CYP3A5* alleles may help to identify specific demographic processes which have affected inter-population differences in allele frequencies, or identify an important role for natural selection in selecting for specific alleles \[[@B44]\]. Under the stepwise mutation model of microsatellite evolution, and assuming no recombination, we estimated the time to the most recent ancestor (TMRCA) of the *CYP3A5\*3* mutation to be 2388 generations (95% confidence intervals \[C.I.\]: 1797--3211) and *CYP3A5\*6* to be 6825 generations (95% C.I.: 3086--11,975). Assuming that a generation is 32 years \[[@B46]\], the estimated age of the *CYP3A5\*3* mutation is \~76,416 years (95% C.I. 57,504-102,752 years) and *CYP3A5\*6* is 218,400 years (95% C.I. 98,752-383,200 years) (Table [6](#T6){ref-type="table"}). Our estimates of the age of *CYP3A5\*3* is consistent with its presence within and outside of Africa. The distribution of the *CYP3A5\*6* allele shows some similarity to that of *FMO2*\**1*, an allele of the gene encoding the drug metabolizing enzyme FMO2 \[[@B33]\]. *FM02\*1* occurs at similar frequencies across Africa and is not found at high frequencies outside of the continent. The estimated age of *FMO2\*1* is 502,404 years (95% C.I. 154,790--1,041,243 years) based on a coalescent simulation \[[@B47]\] and using data from populations re-sequenced as part of the NIEHS SNPs database (<http://egp.gs.washington.edu/>). The age estimates of both the *CYP3A5\*6* and *FMO2\*1* alleles predate estimates of the range-expansion of modern humans out of Africa.

Discussion
==========

We performed an extensive geographic survey of clinically relevant *CYP3A5* alleles in a large African cohort and found highly variable frequencies of the ancestral *CYP3A5\*1* allele (9-96%) across the continent. We estimate that \~43% of individuals within our African dataset express CYP3A5, which is much lower than all other previous estimates for the continent (between 55-95%) \[[@B15],[@B16]\]. The classification of *CYP3A5* alleles as expresser or low/non-expresser will affect estimates of expresser frequencies in Africa. *In vitro* studies of CYP3A5 expression levels in *CYP3A5\*6* homozygotes are needed to establish the effect of the mutation on protein expression. The results from such studies may alter the classification of *CYP3A5\*6* as a clinically relevant *CYP3A5* allele, and mean that CYP3A5 protein expression levels across Africa are likely to be consistent with those presented in Additional file [3](#S3){ref-type="supplementary-material"} Figure S2 . Our estimates of the proportion of CYP3A5 expressers differ across Africa, consistent with the Sahara acting as a barrier to gene flow \[[@B48],[@B49]\]. Additionally, we estimate that the proportion of CYP3A5 expressers in East Africa (\~36%) is lower than in other regions of sub-Saharan Africa (\~45%), and report considerable heterogeneity among Ethiopian ethnic groups (17-54%). We found that the highest frequencies of inferred high-activity phenotypes were seen in equatorial and Niger-Congo speaking populations.

From the geographic survey we observed that the Ethiopian allele frequencies are intermediate between sub-Saharan African and Eurasian groups \[[@B50]\]. Our study has extended previous work on *CYP3A5* in Ethiopia \[[@B51]\] by accounting for, and identifying, considerable inter-ethnic variability within the country. *CYP3A5* haplotype diversity and structure in the Afar, Amhara and Oromo were characteristic of that seen in European Caucasians and Han Chinese individuals. There is a known Arabian contribution to Ethiopian ancestry as a result of migration of Semitic groups into the region, which has influenced genetic diversity \[[@B48],[@B52]\]. We further examined intra-Ethiopian diversity at mitochondrial and Y-chromosome genetic markers and found that the Anuak were outliers. This suggests that the intra-Ethiopian diversity we observed can be explained by Arabian admixture in the Afar, Amhara and Oromo, rather than differential selection pressures on *CYP3A5*.

Considerable intra-African population structuring at the *CYP3A5* gene suggests that there are likely to be multiple pharmacogenetics profiles for key drugs used across the continent, including many used in the treatment and control of malaria \[[@B53]\] and HIV-1 \[[@B54]\]. We identified significant differences between Ethiopians and other sub-Saharan African populations, and intra-Ethiopian diversity, at the *CYP3A5* gene. The results from our study suggest that East Africans are likely to be distinct from a wider cohort of African patients, and that there are likely to be inter-ethnic differences within East Africa. The results from large surveys \[[@B32],[@B33]\], including our study, emphasize the importance of including sub-Saharan African populations in pharmacogenetics research; over 90% of the global disease burden is found in developing countries \[[@B55],[@B56]\]. An appreciable number of the diseases found within the region are treated with CYP3A5 substrates \[[@B5],[@B57]\] at doses optimized for patients with recent European ancestry \[[@B26]\]. Larger and more detailed surveys of clinically important variation in diverse African populations will improve our understanding of how specific drugs and dosages contribute to adverse clinical outcomes within Africa and the African Diaspora. The number of such studies will undoubtedly increase with the availability of newer and cheaper sequencing technologies \[[@B58],[@B59]\] and progression towards the \$1000 genome \[[@B60]\].

We combined our African *CYP3A5\*3* data with those previously published to examine the global prevalence of the allele. We found a significant, positive correlation between *CYP3A5\*3* allele frequencies and latitude, consistent with a previous report \[[@B20]\]. This correlation remained significant when only African data were considered \[Spearmann Rho= 0.666, *p*\<0.0001\]. In contrast we found no significant correlation between latitude and *CYP3A5\*6* or *CYP3A5\*7* frequencies. Given the restricted geographic distribution of the *CYP3A5\*6* allele mainly to Africa, coupled with our estimates of its age (\>200,000 years), it is possible that this allele was lost in a population bottleneck during the range-expansion of humans out of Africa. The heterogeneous distribution of *CYP3A5\*7* in Africa suggests that it arose from a much more recent mutation event and may have spread with the expansion of Niger-Congo speaking populations \~4000 years ago \[[@B61]\]. Nonetheless, the reasons why the derived *CYP3A5\*3*, *CYP3A5\*6* and *CYP3A5\*7* alleles are found at appreciable frequencies in sub-Saharan Africa remains unknown, and the possibility of independent evolutionary causes cannot be discounted. The global distribution of the *CYP3A5\*3* allele is unusual when compared with microsatellite markers, genotyped in samples from the Human Genome Diversity Panel (HDGP-CEPH) \[[@B20]\]. Integrated haplotype scores (iHS) for *CYP3A5\*3* haplotypes in HGDP-CEPH populations sampled from high latitudes north and south of the equator are outliers in the iHS genome-wide distribution (iHS≥2) \[[@B62]\]. iHS scores of *CYP3A5\*3* haplotypes are similar to those of genomic regions surrounding the *LCT* (lactase) and *CD36* genes \[[@B63]\], which have both been reported to have undergone positive selection \[[@B64]-[@B66]\]. It is plausible that an increase in latitude of \~20°, when humans first expanded from East Africa to the Arabian Peninsula, is coupled with specific environmental changes which provided a novel selection pressure. Temperature and precipitation data associated with the Quaternary QUEST project (accessed through the British Atmospheric Centre: <http://badc.nerc.ac.uk/home/index.html>) suggest that changes in precipitation over the past 50,000 years are greater than those in temperature. However we did not find any significant correlation between precipitation values and *CYP3A5* allele frequencies. We did observe negative correlations between inferred expression phenotypes (assuming *CYP3A5\*6* is a low/non-expresser allele) and aridity values for the Holocene \[Spearmann's Rho= −0.465, *p*=0.004\] and Late Pleistocene \[Spearmann's Rho= −0.379, *p*=0.02\]. Under the de Martonne aridity index, this means that high frequencies of high-activity alleles are positively correlated with arid and semi-arid environments \[[@B34]\]. This finding is consistent with the hypothesis that high-activity *CYP3A5* alleles may be adaptive in regions where there are frequent water shortages, by aiding the rapid retention of water \[[@B20]\]. However, stronger correlations were found with temperature alone. Although further work will be needed to confirm these ecological correlations, the strong correlation with temperature is consistent with what we would expect for functional variation of genes involved in heat adaptation \[[@B21]\]. However, we cannot rule out that there may be an, as yet untested, ecological variable which may have provided a selective pressure.

We have provided the first estimate of the age of the *CYP3A5\*3* allele as \~76,000 years (95% C.I. 57,504-102,752 years), using a closely linked microsatellite. This estimate is consistent with the wide geographic distribution of *CYP3A5\*3*, both inside and outside Africa although not with the low haplotype diversity \[[@B20],[@B67]\] and high iHS scores \[[@B62]\] previously reported. This may be because the allele age estimation presented here was made using Ethiopian data whereas the previously reported low haplotype diversity \[[@B20],[@B67]\] and high iHS scores \[[@B62]\] were based on non-African samples. It is also possible that the microsatellite mutation rate for rs10536492 differs from the genome wide average for dinucleotide repeats \[[@B68]\], which would influence the age estimates, or that the extensive LD on haplotypes containing *CYP3A5\*3* is explained by unusually low recombination rates in that genomic region. Finally, while the correlations between the *CYP3A5\*3* geographic distribution and ecological variables relating to temperature and aridity, as well as previously reported low haplotype diversity \[[@B20],[@B67]\] and high iHS scores \[[@B62]\], both independently support the hypothesis that the *CYP3A5\*3* allele is adaptive, alternative targets of positive selection on the same haplotype background may exist and both they (if present) and the *CYP3A5\*3* allele may have been differentially selected inside and outside Africa.

Conclusions
===========

The data that we present complement and extend work in previous publications which reported evidence of geographically restricted positive selection on the *CYP3A5* gene \[[@B20],[@B25],[@B26],[@B69]\]. In addition to improved knowledge of the effect and distribution of clinically relevant genetic variation, our approach highlights the importance of considering population history and of utilizing evolutionary approaches in clinical research. Evolutionary approaches to genetic studies are likely to identify additional populations that require targeted health interventions. Further studies which characterize variation in medically important genes in ethnically and geographically diverse global populations are needed as we progress towards personalized clinical medicine, a key goal of the genomics revolution \[[@B70]\].

Methods
=======

Samples
-------

The DNA samples analyzed in this study were part of a collection at The Centre for Genetic Anthropology at University College London. Samples were collected anonymously and with informed consent (verbal in Africa) from ostensibly healthy individuals, between 1998--2007, from specified locations in and around Africa \[ethical approval: UCLH 99/0196\]. Additional ethical approval was obtained for Ethiopian collections from the National Health Research Ethical Clearance Committee under the Ethiopian Science and Technology Commission in Addis Ababa. All samples have been previously used in studies on clinically relevant genes \[[@B31]-[@B33]\]. For analyses, individuals were grouped by the collection location or by ethnicity (Additional file [5](#S5){ref-type="supplementary-material"} Table S2). Samples were not grouped according to country as the partitioning of much of the African continent by colonial powers was recent and largely irrespective of ethnic identities \[[@B71]\]. 1028 *CYP3A5\*1/\*3* genotypes for 51 global populations, from the Human Genome Diversity Panel-Centre d'Etude du Polymorphisme Humain (HGDP-CEPH) collection, which had previously been published \[[@B20]\] were combined with the 2538 sample cohort genotyped for this study. *CYP3A5* re-sequencing data, which were previously published, for 70 individuals from three distinct ethnic groups from the Coriell Repositories (24 European Caucasians, 23 African-Americans and 23 Han Chinese individuals) were combined with the Ethiopian cohort for detailed integrative analyses \[[@B20]\]. Published data were provided by Dr Emma Thompson from the University of Chicago.

Genotyping and re-sequencing
----------------------------

*Genotyping of clinically relevant CYP3A5 alleles;* Genotyping of *CYP3A5\*1, CYP3A5\*3, CYP3A5\*6* and *CYP3A5\*7* was performed using TaqMAN allelic discrimination technology \[ABiosystems product code: C_26201809_30 for *CYP3A5\*1/\*3,* and ABiosystems product code: C_30203959 for *CYP3A5\*6*\], and KASPar (performed externally by KBiosciences®, UK).

*Re-sequencing of CYP3A5;* The 13 exons and their flanking introns, promoter region and 3´ untranslated of *CYP3A5* were amplified in 379 Ethiopian individuals using primers designed on the basis of the *CYP3A5* reference sequence in NCBI Build 132 \[(<http://www.ncbi.nlm.nih.gov/>) (see Additional file [6](#S6){ref-type="supplementary-material"} Table S3 for a list of primers)\]. Amplicons were sequenced using ABI PRISM Dye Terminators version 3.1 on an ABI 96-capillary 3730×l DNA Analyzer according to the manufacturer's protocol (Applied Biosystems, Applera, UK). Part of the *CYP3A5* gene was re-sequenced externally by Macrogen®, USA.

*Microsatellite genotyping;* A --GT microsatellite, located \~1500 base pairs downstream of the 3´ end of *CYP3A5* was genotyped in 379 Ethiopian individuals, for whom re-sequencing data were also generated. Microsatellite genotyping was performed using a high-throughput method adapted from \[[@B72]\]. A 456 base pair region of *CYP3A5,* approximately \~1000 base pairs downstream of the 3´ UTR was amplified using the forward primer 5´-AATATATGTGTTTGTATGTGTG-3´ and a fluorescently labeled reverse primer FAM-AAGTGCTACCAATTTTGTACGT-3´. PCR amplification was performed in 10 μl reaction volumes containing 1ng of template DNA, 0.5 μM of primers, 0.2 units *Taq* DNA polymerase (HT Biotech, Cambridge, UK), 0.2 μmol dNTPs, 0.1 μmol of 10X Buffer IV (Thermo Scientific®) and 0.28 μl of magnesium chloride (concentration 25 mM). Cycling conditions were 5 minutes of pre-incubation at 95°C, followed by 38 cycles of 95°C for one minute, 58°C for 40 seconds, 72°C for 40 seconds, with a final elongation step at 72°C for 10 minutes. Following amplification, a 1.1 μl aliquot of amplified PCR product was added to 9.89 μl of high purity (HiDi) formamide and 0.11 μl of ROX-500 size standard (Applied Biosystems, Warrington, UK). Samples were run on an ×3730 DNA Analyzer and analyzed using GeneMapper 4 software (Applied Biosystems, Warrington UK).

Data analyses
-------------

*Molecular diversity and Population genetics*; exact tests of deviation from Hardy-Weinberg equilibrium (using 10,000 steps in a Markov chain), pairwise *F*~ST~, and AMOVA, were all performed using Arlequin 3.5 \[[@B73]\]. Pairwise *F*~ST~ estimates were used to perform principal co-ordinates analysis in the R-programming environment using routines in the APE package. The *D´* measure of linkage disequilibrium was calculated using the expectation maximization algorithm using LDMax (part of the GOLD software package, freely available at: <http://www.sph.umich.edu/csg/abecasis/GOLD/docs/ldmax.html>). Haplotypes were inferred using PHASE version 2.1 (1000 iterations, 500 burn-in) \[[@B74]\]. Singletons were removed for haplotype and LD analysis. Haplotype networks were constructed using a median-joining network implemented in Network 4.6.1 and re-colored using Adobe PhotoShop CS4. Nucleotide diversity, tests for departures from neutrality, Fay and Wu's H test and the HKA test were all performed using DnaSP 5.0 \[[@B75]\]. The chimpanzee *CYP3A5* gene sequence was downloaded from NCBI (<http://www.ncbi.nlm.nih.gov/>).

*Ecological correlations;* geographic co-ordinates were used to calculate distance from the equator (in kilometers) using the online programme: <http://www.movable-type.co.uk/scripts/latlong.html>. Raw ecological data for temperature (in degrees Celsius) and precipitation (in mm), at each set of geographic co-ordinates, for 0, 10,000 and 50,000 years ago were extracted from the British Atmospheric Data Centre (<http://badc.nerc.ac.uk/home/index.html>), from the ALL-5G dataset associated with the Quaternary QUEST (<http://researchpages.net/QQ/>) \[[@B76]\]. The data were extracted using Python. The raw data have a resolution of 5 degrees latitude and 7.5 degrees longitude and were interpolated to a resolution of 1 degree latitude and 1 degree longitude. The interpolations were done using the smooth.2d function in the fields library of the R-programming environment. An estimate of relative aridity was inferred from extracted temperature and precipitation values corresponding to each geographic location using the de Martonne aridity index \[[@B34]\]. Mantel and partial Mantel tests were performed in the R-programming environment using routines in the APE package \[[@B77]\] and ecodist package \[[@B78]\] respectively.

*Bioinformatics analyses of genetic variation on protein expression and function;* cross-species alignments of *CYP3A5* orthologues (sequences obtained from NCBI: <http://www.ncbi.nlm.nih.gov/>) were performed using ClustalW software (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>). Analyses of regulatory motifs in the *CYP3A5* promoter were performed using MatInspector \[[@B79]\], effects of amino acid substitutions on the structure and function of CYP3A5 were performed using PolyPhen2 \[[@B80]\], predictions of mutations which are likely to affect gene splicing were performed using the online Berkeley Drosophila Genome Project splice predictor \[[@B81]\].

*Estimating the age of the clinically relevant CYP3A5 variants*; The gametic phase of CYP3A5 mutations and the --GT microsatellite (rs10536492) was not determined empirically. Allele ages were estimated using data for individuals homozygous for particular haplotypes. As no Ethiopian individual was identified to be a *CYP3A5\*7* homozygote, this variant could not be dated. Under the stepwise mutation model the variance (ASD) in the microsatellite repeat length, from the most recent common ancestor, is a linear function of the mutation rate (μ) and coalescence time in generations (t); ASD=μt \[[@B82],[@B83]\]. A mutation rate of 4.5×10^-4^ was used to estimate the time to the most recent common ancestor (MRCA) based on average estimates of the mutation rate of dinucleotide microsatellites in the human genome \[[@B68],[@B84]\].

ASD and t were calculated using Ytime software \[[@B85]\]. The microsatellite length of the ancestral MRCA is assumed to be known. For this study the ancestral length of the microsatellite was estimated to be 35; as the majority of *CYP3A5\*1* haplotypes had 35 repeats. Confidence intervals for the age estimates were obtained from calculating the distances between the ancestral and derived chromosomes under a star-genealogy model; based on the results of network analysis of *CYP3A5* haplotypes. A generation was assumed to be 32 years \[[@B46]\].
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###### Additional file 1

**Table S1.**"The proportion of each inferred *CYP3A5* haplotype observed in each population." The Table lists the frequencies of each inferred *CYP3A5* haplotype, by population.
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###### Additional file 2

**Figure S1.** "The distribution of high-, intermediate- and low- CYP3A5 expression phenotypes, inferred from diplotypes." The Figure shows inferred CYP3A5 expression phenotypes, assuming that *CYP3A5\*6* causes low/non-expression of CYP3A5. The size of each circle is proportional to the number of individuals sampled from a given population (see Additional file Table S1).
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###### Additional file 3

**Figure S2.** "The distribution of high-, intermediate- and low- CYP3A5 expression phenotypes, inferred from diplotypes." The Figure shows inferred CYP3A5 expression phenotypes, assuming that *CYP3A5\*6* does not cause low/non-expression of CYP3A5. The size of each circle is proportional to the number of individuals sampled from a given population (see Additional file Table S1).
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###### Additional file 4

**Figures S3a and b.** "Haplotypes inferred from genotype data in 8 populations." Supplementary Figure 3a shows the composition of each *CYP3A5* haplotype inferred from genotype data for 8 global populations. The frequencies of each haplotype, by population, are shown in Additional file Figure S3b.
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###### Additional file 5

**Table S2.** "Geographic co-ordinates, sample size and major language family of each population genotyped in the geographic survey of clinically relevant *CYP3A5* alleles. The *CYP3A5* gene was re-sequenced in five Ethiopian populations." This Table provides details of all populations which were genotyped, and re-sequenced for this study.
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###### Additional file 6

**Table S3.** "A list of the primers used for PCR amplification and sequencing of *CYP3A5*."
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